Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 9/20 | 0.63 |
| ▸ | SMARCA4 | P51532 | 8/20 | 0.63 |
| ▸ | EGFR | P00533 | 3/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10502486 | 0.87 | SMARCA2 (0.62) | SMARCA2SMARCA4PIK3CAMAPK8MAPK9 | |
| SCHEMBL9599510 | 0.84 | SMARCA2 (0.59) | SMARCA2SMARCA4ALDH1A1HTT | |
| SCHEMBL9599834 | 0.84 | SMARCA2 (0.86) | SMARCA2SMARCA4ALDH1A1CNR1MEN1 | |
| SCHEMBL3322673 | 0.83 | SMARCA2 (0.66) | SMARCA2SMARCA4PIK3CAMAPK8MAPK9 | |
| SCHEMBL31718481 | 0.81 | SMARCA2 (0.61) | SMARCA2SMARCA4ALDH1A1MEN1KMT2A | |
| SCHEMBL3324675 | 0.79 | SMARCA2 (0.64) | SMARCA2SMARCA4 | |
| SCHEMBL10560427 | 0.79 | SMARCA2 (0.61) | SMARCA2SMARCA4PIK3CAMAPK8MAPK9 | |
| SCHEMBL2958982 | 0.79 | MDM2 (0.62) | SMARCA2SMARCA4MEN1KMT2AKDM4E | |
| SCHEMBL22125200 | 0.78 | SMARCA2 (1.00) | SMARCA2SMARCA4MEN1KMT2AMAPT | |
| SCHEMBL22125520 | 0.78 | SMARCA2 (0.76) | SMARCA2SMARCA4CNR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2702052-B1 | 17ALPHA-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2017-10-18 | — | — | EP | disclosed |
| EP-2702052-B1 | 17ALPHA-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2017-10-18 | — | — | EP | disclosed |
| US-9339501-B2 | 17a-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2016-05-17 | — | — | US | disclosed |
| US-9339501-B2 | 17a-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2016-05-17 | — | — | US | disclosed |
| US-9339501-B2 | 17a-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2016-05-17 | — | — | US | disclosed |
| US-20150209356-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-20150209356-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-20150209356-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-9029399-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-05-12 | — | — | US | disclosed |
| US-9029399-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-05-12 | — | — | US | disclosed |
| US-20140228386-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| US-20140228386-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| EP-2702052-A1 | 17ALPHA-HYDROXYLASE/C17,20-LYASE INHIBITORS | Novartis AG (CH) | 2014-03-05 | — | — | EP | disclosed |
| WO-2012149413-A1 | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012149413-A1 | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2012-11-01 | — | — | WO | disclosed |
| EP-0243450-B1 | PYRIDINYLUREA COMPOUNDS AND AGRICULTURAL USES | FMC Corporation (US) | 1993-04-28 | — | — | EP | disclosed |
| EP-0243450-A4 | PYRIDINYLUREA COMPOUNDS AND AGRICULTURAL USES. | FMC CORP (US) | 1989-09-11 | — | — | EP | disclosed |
| US-4818271-A | PLANT GROWTH REGULATORS | FMC CORPORATION (US) | 1989-04-04 | — | — | US | disclosed |
| EP-0243450-A1 | PYRIDINYLUREA COMPOUNDS AND AGRICULTURAL USES. | FMC CORP (US) | 1987-11-04 | — | — | EP | disclosed |
| WO-1987002665-A1 | PYRIDINYLUREA COMPOUNDS AND AGRICULTURAL USES | FMC CORPORATION (US) | 1987-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150209356-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | CYP17A1, CYP21A2, HSD17B1 | SMARCA2 3948/4885SMARCA4 3706/4885EGFR 1674/4885 |
| US-20140228386-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | CYP17A1, CYP21A2, HSD17B1 | SMARCA2 3948/4885SMARCA4 3706/4885EGFR 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.